IL-1 beta (蛋白 | 抗体 | cDNA 克隆 | ELISA 试剂盒)

All IL-1 beta reagents are produced in house and quality controlled, including 28 IL-1 beta Antibody, 1 IL-1 beta ELISA, 78 IL-1 beta Gene, 11 IL-1 beta Protein, 3 IL-1 beta qPCR. All IL-1 beta reagents are ready to use.

IL-1 beta Antibody (28)

IL-1 beta ELISA 试剂盒(即用型)& ELISA 抗体对套装(非即用型)(1)

IL-1 beta cDNA Clone (78)

NM_000576.2

克隆载体 cDNA 产品

In lentiviral vector

NM_008361.3

克隆载体 cDNA 产品

In lentiviral vector

NM_031512.2

克隆载体 cDNA 产品

In lentiviral vector

NM_001082201.1

克隆载体 cDNA 产品

In lentiviral vector

NM_001037971.1

克隆载体 cDNA 产品

In lentiviral vector

NM_001042756.1

克隆载体 cDNA 产品

In lentiviral vector

IL-1 beta 分子背景

Interleukin-1 beta (IL1 beta or IL1B) also known as catabolin, is a member of the interleukin 1 cytokine family. IL1 is a pleiotropic cytokine. It is involved in the inflammatory response, cell growth, and tissue repair in the cortex. The IL1 superfamily consists of three members, IL1A (IL1 alpha), IL1B (IL1 beta), and IL1 receptor antagonist (IL1Ra). In clinical, it has been reported that Interleukin (IL)-1 may influence Th1 / Th2 immune responsiveness and has been implicated in the establishment of successful pregnancy. Proinflammatory interleukin (IL)-1 gene polymorphisms associated with high levels of IL-1beta activity increase the risk for hypochlorhydria and distal gastric carcinoma. IL1B polymorphisms may be involved in susceptibility to SSc. Moreover, the IL2-384-G allele may be a marker for the limited phenotype of systemic sclerosis (SSc).

IL-1 beta 参考文献

  • Kim SH, et al. (2008) Association of -31TC and -511 CT polymorphisms in the interleukin 1 beta (IL1B) promoter in Korean keratoconus patients. Mol Vis. 14:2109-16.
  • Wang ZC, et al. (2002) T helper 1-type immunity to trophoblast antigens in women with a history of recurrent pregnancy loss is associated with polymorphism of the IL1B promoter region. Genes Immun. 3(1): 38-42.
  • Mattuzzi S, et al. (2007) Association of polymorphisms in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis. J Rheumatol. 34(5): 997-1004.